Your friends are fundraising. Don't miss out, opt in.

Blood Cancer UK

Amwins Global Risks

We've chosen the Matthew Wilson Multiple Myeloma Fund (MWMF), part of Blood Cancer UK, as our corporate charity for 2023/24.
£75,582
raised
RCN 216032

Be a fundraiser

Create your own fundraising page and help support this cause.

Start fundraising

Story

We've chosen the Matthew Wilson Multiple Myeloma Fund (MWMF), part of Blood Cancer UK, as our corporate charity for 2023/24.

Former Brit CEO Matthew Wilson was diagnosed with multiple myeloma, a form of blood cancer, in 2021, and has since set up the MWMF.

Over 40,000 people are diagnosed with blood cancer in the UK each year, and over 250,000 people are currently living with blood cancer, including Matthew himself, as there is no cure for multiple myeloma. You can read more about blood cancer here.

The MWMF has already raised nearly £3m and aims to raise as much as possible over the next few years. We'll be doing this through a variety of fundraisers, which we'll post more about here as they come.

Please donate to help us achieve our goal of raising £100,000 in the next two years. Every contribution, no matter its size, will make a difference.

Thank you for your support!

Share this story

Help Blood Cancer UK

Sharing this page with your friends could help raise up to 3x more in donations

You can also help by sharing this link on

About the charity

Blood Cancer UK

Verified by JustGiving

RCN 216032
We're dedicated to beating blood cancer. We fund research and support those affected. Since 1960, we've invested over £500 million in blood cancer research, transforming treatments and saving lives. The day we beat blood cancer is now in sight and our researchers are determined to finish the job.

Donation summary

Total raised
£75,581.59
+ £3,252.00 Gift Aid
Online donations
£23,993.59
Offline donations
£51,588.00
Direct donations
£325.00
Donations via fundraisers
£23,668.59

* Charities pay a small fee for our service. Find out how much it is and what we do for it.